<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818908</url>
  </required_header>
  <id_info>
    <org_study_id>JSPH-HLH-001</org_study_id>
    <nct_id>NCT01818908</nct_id>
  </id_info>
  <brief_title>Trial of DA-EPOCH Regimen for NHL With HLH</brief_title>
  <official_title>Clinical Study of Dose-adjusted EPOCH Regimen for Non-Hodgkin's Lymphoma With Hemophagocytic Lymphohistiocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major purpose of this clinical study is to assess clinical outcome of dose-adjusted EPOCH
      regimen for patients with non-Hodgkin's lymphoma(NHL)-associated hemophagocytic
      lymphohistiocytosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphoma-associated hemophagocytic lymphohistiocytosis(LA-HLH) has a high fatality rate and
      the worst outcome. The major cause of LA-HLH is aggressive non-Hodgkin's lymphoma(NHL),
      especially T/NKT cell lymphomas. Until now, there is no recommended therapeutic schedule for
      this fatal disease. Dose-adjusted(DA) EPOCH (etoposide, prednisone, vincristine,
      cyclophosphamide, and doxorubicin) shows effective activity in patients with aggressive NHL.
      The investigators therefore developed DA-EPOCH regimen to treat non-Hodgkin's lymphoma with
      hemophagocytic lymphohistiocytosis and assess its clinical outcome including safety and
      efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>one year</time_frame>
    <description>overall response rate after treated by DA-EPOCH regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Response</measure>
    <time_frame>four weekd after treatment of DA-EPOCH</time_frame>
    <description>To determine the median time to overall response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>one year</time_frame>
    <description>progression free survival after treatment of DA-EPOCH regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
    <description>overall survival after treatment of DA-EPOCH regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>up to 30 days after last dose of treatment</time_frame>
    <description>Number of Participants with Adverse Events, and evaluated standard is according to common terminology criteria adverse events(CTCAE) version 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>NHL With Hemophagocytic Lymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>DA-EPOCH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infused agents:
Etoposide 50 mg/m2/day CI24h d1-d4; Doxorubicin 10 mg/m2/day CI24h d1-d4; Vincristine 0.4mg/m2/day CI24h d1-d4;
Bolus agents:
Rituximab(B-NHL) 375 mg/m2/day IV d0; Cyclophosphamide 750 mg/m2/day IV d5 ; Prednisone 60 mg/m2/bid oral or IV d1-d5;
The details of dose adjustment are described in ref 1.
If enrolled patient was histologically confirmed CD20+ B cell lymphoma, standard dose of rituximab will be recommend to combined with DA-EPOCH regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-EPOCH</intervention_name>
    <description>DA-EPOCH regimen</description>
    <arm_group_label>DA-EPOCH</arm_group_label>
    <other_name>Infused agents</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Doxorubicin</other_name>
    <other_name>Vincristine</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Prednisone</other_name>
    <other_name>Rituximab(B-NHL)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed non-Hodgkin's lymphoma;

          2. Patients whose clinical findings satisfy either of HLH 2004 standard or ASH2009
             standard:

             HLH2004 standard at least 5 criteria out of the following: Fever ≥ 38.5 ℃ for ≥ 7
             days; hepatosplenomegaly; Cytopenias affecting ≥ 2 of 3 lineages in PB Hb &lt; 9 g/L
             Platelet &lt; 100 x 109 /L ANC &lt; 1.0 x 109 /L; Hypertriglyceridemia and/or
             hypofibrinogenemia (fasting triglycerides ≥ 265 mg/dL, fibrinogen ≤ 1.5 g/L);
             Hemophagocytosis in BM or spleen or LN; Low or absent NK-cell activity ( according to
             local laboratory reference); Serum-ferritin ≥ 500 mcg/L ; Soluble CD25(sIL-2 receptor)
             ≥ 2,400 U/ml ;

          3. New-diagnosed and untreated;

          4. Understand and voluntarily sign an informed consent form, able to adhere to the study
             visit schedule and other protocol requirements.

        ASH2009 Standard

          1. .At least 3 of 4:

               1. Fever

               2. Splenomegaly

               3. Cytopenias (minimum 2 cell lines reduced)

               4. Hepatitis

          2. . And at least 1 of 4:

               1. Hemophagocytosis

               2. ↑ Ferritin

               3. ↑ sIL2Rα (age based)

               4. Absent or very decreased NK function 4. Other results supportive of HLH
                  diagnosis:

               1. Hypertriglyceridemia

               2. Hypofibrinogenemia

               3. Hyponatremia

        Exclusion Criteria:

          1. Primary HLH.

          2. HLH from rheumatic disorder (such as SLE, AOSD, antiphospholipid antibody syndrome)

          3. Pregnancy (as determined by serum or urine test) or active breast feeding

          4. Concomitant malignancy other than non-Hodgkin's lymphoma and need to treat;

          5. Concomitant with other hematologic diseases(such as leukemia,hemophilia primary
             myelofibrosis) which investigator it unsuitable to be enrolled into this clinical
             trial;

          6. Any potential drug abuse, medical, psychological or social conditions which may
             disturb this investigation and assessment.

          7. In any conditions which investigator considered ineligible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Xu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LEI FAN, M.D., Ph.D.</last_name>
    <phone>+86 25 6813 6034</phone>
    <email>fanlei_fl@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>ChangZhou No.2 People's Hospital</name>
      <address>
        <city>ChangZhou</city>
        <state>Jiangsu</state>
        <zip>213011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Zhou, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Min Zhou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HuaiAn First People's Hospital</name>
      <address>
        <city>HuaiAn</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Yu, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Liang Yu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JiangSu Province Hospital</name>
      <address>
        <city>NanJing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LEI FAN, Dr.</last_name>
      <phone>86 25 6813 6034</phone>
    </contact>
    <investigator>
      <last_name>WEI XU, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WuXi People's Hospital</name>
      <address>
        <city>WuXi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Zhuang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>YunFeng Shen, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002 Apr 15;99(8):2685-93.</citation>
    <PMID>11929754</PMID>
  </reference>
  <reference>
    <citation>Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31.</citation>
    <PMID>16937360</PMID>
  </reference>
  <reference>
    <citation>Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008 Jun 1;26(16):2717-24. doi: 10.1200/JCO.2007.13.1391. Epub 2008 Mar 31.</citation>
    <PMID>18378569</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2013</study_first_submitted>
  <study_first_submitted_qc>March 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2013</study_first_posted>
  <last_update_submitted>March 23, 2013</last_update_submitted>
  <last_update_submitted_qc>March 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>WEI XU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>non-Hodgkin's lymphoma</keyword>
  <keyword>hemophagocytic lymphohistiocytosis</keyword>
  <keyword>DA-EPOCH</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

